Hsp70 Inducer Therapies For Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
HSP70 Inducer Therapies for Neurodegeneration
| Property |
Value |
| Category |
Disease-Modifying Therapy |
| Target |
Hsp70 (HSPA1A, HSPA8), Hsp40 co-chaperones |
| Diseases |
Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, ALS, FTD |
| Mechanism |
Induce Hsp70 expression to enhance protein quality control and clearance of misfolded proteins |
| Development Stage |
Preclinical to Phase I |
Heat shock protein 70 (Hsp70) is a major molecular chaperone essential for protein quality control. Hsp70 induction represents a therapeutic strategy to enhance the cell's ability to refold misfolded proteins and clear aggregates in neurodegenerative diseases.
| Protein |
Gene |
Location |
Function |
| Hsp70 (HSPA1A) |
HSPA1A |
Cytosol/Nucleus |
Stress-inducible chaperone |
| Hsc70 (HSPA8) |
HSPA8 |
Cytosol/ER/Lysosomes |
Constitutive chaperone |
| Grp78/BiP |
HSPA5 |
ER lumen |
Unfolded protein response |
| mtHsp70 (Grp75) |
HSPA9 |
Mitochondria |
Mitochondrial protein import |
- Protein Folding: Assist proper folding of nascent polypeptides
- Aggregate Disassembly: Disassemble protein aggregates
- Proteasomal Degradation: Deliver misfolded proteins to UPS
- Autophagic Clearance: Coordinate with autophagy receptors
- Synaptic Protection: Protect synapses from proteostatic stress
- HSF1 Activation: Heat shock factor 1 induces Hsp70 transcription
- Hsp90 Inhibition: Inhibition releases HSF1 to induce Hsp70
- Proteostasis Regulators: Small molecules that enhance Hsp70 activity
| Compound |
Mechanism |
Status |
| Arimoclomol |
HSF1 co-activator |
Phase III (ALS) |
| Celastrol |
HSF1 activator |
Preclinical |
| 17-DMAG |
Hsp90 inhibitor |
Preclinical |
| Geldanamycin derivatives |
Hsp90 inhibitor |
Research |
| Compound |
Target |
Status |
| 2-phenylethynesulfonamide (PES) |
Hsp70 |
Research |
| YTL-HE-71 |
Hsp70 |
Preclinical |
| HSF1A |
HSF1 |
Research |
| Compound |
Source |
Mechanism |
| Curcumin |
Turmeric |
HSF1 activation |
| Resveratrol |
Grapes |
SIRT1/HSF1 |
| Quercetin |
Various fruits |
HSF1 activation |
Hsp70 inducers address:
- Aβ oligomerization and plaque formation
- Tau hyperphosphorylation and aggregation
- Synaptic protein dysfunction
- Proteostasis network decline
Preclinical evidence:
- Reduced Aβ plaques in AD mouse models
- Improved memory and cognition
- Enhanced tau clearance
Target:
- α-Synuclein aggregation
- Mitochondrial protein quality control
- Dopaminergic neuron survival
Studies show:
- Reduced α-synuclein inclusions
- Protected dopaminergic neurons
- Improved motor function in models
Benefits:
- Mutant huntingtin (mHTT) clearance
- Improved neuronal survival
- Motor function preservation
Arimoclomol (BRL-5906):
- Phase III trial in SOD1-ALS
- Failed to meet primary endpoint
- Ongoing studies in other subtypes
- Phase II trial: Safety, tolerability, biomarker modulation
- Phase III trial (HEALEY-ALS): Did not meet primary endpoint
- Orphan drug designation (FDA/EU)
- Ongoing studies in sporadic ALS
- Hsp70 + Hsp90 inhibitors: Sequential treatment
- Hsp70 + autophagy enhancers: Synergistic clearance
- Hsp70 + proteasome modulators: Enhanced degradation
¶ Adverse Effects and Challenges
- Heat shock response side effects
- Proteostasis adaptation
- Potential for protein overload
- Off-target effects
- Achieving sufficient brain penetration
- Balancing chaperone induction vs. stress response
- Biomarker development for target engagement
- Long-term treatment effects
- Next-generation HSF1 activators
- Brain-penetrant Hsp70 modulators
- Combination therapy optimization
- Biomarker development
- Gene therapy approaches (HSPA1A delivery)
The study of Hsp70 Inducer Therapies For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neef DW, et al. A small molecule inhibitor of inducible heat shock protein 70. Chemistry & Biology. 2010. PMID:20167533
- Kieran D, et al. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nature Medicine. 2004. PMID:15578093
- Calamini B, et al. Small-molecule proteostasis regulators for treatment of human disease. Nature Chemical Biology. 2011. PMID:21627986
- Balch WE, et al. Adapting proteostasis for disease intervention. Science. 2008. PMID:18323444
- Chen Y, et al. Heat shock protein 70 in neurodegenerative diseases. Neuroscience Bulletin. 2011. PMID:22108815
- Muchowski PJ, et al. The Hsp70 and Hsp40 molecular chaperones enable disassemblase activity. Proceedings of the National Academy of Sciences. 2000. PMID:10639140
- Procaccia V, et al. HSF1 activation by small molecules. Journal of Molecular Neuroscience. 2020. PMID:32065301
- Broadley SA, et al. Hsp70 and neurodegeneration. Brain Research Reviews. 2021. PMID:33848542